Pramod Gupta - Unicycive Therapeutics Executive Operations
| UNCY Stock | USD 0.68 0.03 4.62% |
Executive
Pramod Gupta is Executive Operations of Unicycive Therapeutics
| Age | 65 |
| Address | 4300 El Camino Real, Los Altos, CA, United States, 94022 |
| Phone | 650 351 4495 |
| Web | https://unicycive.com |
Pramod Gupta Latest Insider Activity
Tracking and analyzing the buying and selling activities of Pramod Gupta against Unicycive Therapeutics stock is an integral part of due diligence when investing in Unicycive Therapeutics. Pramod Gupta insider activity provides valuable insight into whether Unicycive Therapeutics is net buyers or sellers over its current business cycle. Note, Unicycive Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Unicycive Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Pramod Gupta over three weeks ago Acquisition by Pramod Gupta of 41845 shares of Unicycive Therapeutics at 0.49 subject to Rule 16b-3 | ||
Pramod Gupta over a year ago Acquisition by Pramod Gupta of 1355000 shares of Unicycive Therapeutics subject to Rule 16b-3 |
Unicycive Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.6285) % which means that it has lost $0.6285 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4705) %, meaning that it created substantial loss on money invested by shareholders. Unicycive Therapeutics' management efficiency ratios could be used to measure how well Unicycive Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 6.42 in 2025, whereas Return On Tangible Assets are likely to drop (2.03) in 2025. At this time, Unicycive Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 16.2 M in 2025, whereas Non Currrent Assets Other are likely to drop (164.4 K) in 2025.Similar Executives
| Found 6 records | EXECUTIVE Age | ||
| Daniel MD | Transcode Therapeutics | 73 | |
| RN MBA | Transcode Therapeutics | N/A | |
| Alan Freidman | Transcode Therapeutics | N/A | |
| Khullani JD | Cardio Diagnostics Holdings | 41 | |
| Esq JD | Cardio Diagnostics Holdings | 60 | |
| Calais Pharm | Transcode Therapeutics | 65 | |
Management Performance
| Return On Equity | -1.47 | ||||
| Return On Asset | -0.63 |
Unicycive Therapeutics Leadership Team
Elected by the shareholders, the Unicycive Therapeutics' board of directors comprises two types of representatives: Unicycive Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Unicycive. The board's role is to monitor Unicycive Therapeutics' management team and ensure that shareholders' interests are well served. Unicycive Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Unicycive Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MPA MD, Chairman, Founder | ||
| Pramod Gupta, Executive Operations | ||
| John CPA, Chief Officer | ||
| Douglas MBA, Executive Strategy |
Unicycive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Unicycive Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.47 | ||||
| Return On Asset | -0.63 | ||||
| Current Valuation | 35.82 M | ||||
| Shares Outstanding | 103.8 M | ||||
| Shares Owned By Insiders | 6.12 % | ||||
| Shares Owned By Institutions | 60.39 % | ||||
| Number Of Shares Shorted | 795.15 K | ||||
| Price To Book | 2.42 X | ||||
| Price To Sales | 62.82 X | ||||
| Revenue | 675 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.